Rights and permissions
About this article
Cite this article
Natalizumab or fingolimod in RRMS in Sweden?. Pharmacoecon. Outcomes News 653, 7 (2012). https://doi.org/10.2165/00151234-201206530-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206530-00018